DexCom Inc (NASDAQ: DXCM) disclosed the 2025 financial targets revision at its investor day last week. The company raised the outlook for revenue to $4.6 billion - $5.1 billion (from $4.0 billion - $4.5 billion), adjusted operating profit margin to 21% (from 20%), and adjusted EBITDA margin to 31% (from 30%) for 2025. On the other hand, the company reiterated 2025 guidance for an adjusted gross margin of 65%. "Dexcom continues to execute on our vision to drive better health outcomes throughout t
Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dexcom Updates Long-Range Financial Targets streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New Dexcom product with 15-day wear, a cash-pay option and a tailored software experience for people who don't use insulin is expected to launch in the U.S. in 2024 Access and availability of Dexcom CGM is expanding